According to the Lithuanian startup Vital3D, humane organs could be biopriated for transplants within 10 years. Before the company reaches human hearts and kidneys, it begins with something easier: regeneration of the dog skin.
Vital3D is based in Vilnius and is already bioprinting functional fabric structures. Using a proprietary laser system, the start -up deposits store living cells and biomaterials in precise 3D patterns. The structures imitate natural biological systems – and one day could form entire organs that are tailored to the unique anatomy of a patient.
This mission is both professionally and personally for CEO Vidmantas Šakalys. After losing a mentor against urine cancer, he started developing 3D printed kidneys that were able to save others from the same fate. Before he reaches this goal, the company needs a commercial product to finance the long way to finance us.
This product is important-and the first biofold wound paving for pets. Dogs are the initial goal, whereby human applications should follow.
Pernilla Sjöholm, The Tinder Swindler Survivor on stage on the TNW Conference 2025
Listen to your story and how to develop a startup to prevent fraud and fraud with technology on June 19.
Šakalys calls the patch “a first step” towards Bioprinted kidney. “Printing organs for transplantation is a really challenging task,” he says TNW after a tour of his laboratory. “It will be removed from now on in 10 or 15 years, and as a commercial unit we have to have products available in stores. So we start with simpler products and then switch to more difficult.”
The path may be easier, but the technology is anything but.
Bioprinting goes to the vet
Vitalheal is embedded with growth factors that accelerate skin regeneration.
On the surface of the pavement, tiny pores enable about a fifth of the width of human hair, while bacteria block air circulation. As soon as vital heal has been used, it seals the wound and retains a constant pressure, while the growth factors get to work.
According to Vital3D, the patch can shorten the healing time from 10 to 12 weeks to just four to six. The risk of infection can drop from 30% to less than 10%, visits to the vet from eight to two or three and half of the operation.
Current treatments, according to the startup, can be costly, ineffective and stressful for animals. Vitalheal is designed in such a way that it offers a safer, faster and cheaper alternative.
Vital3D says the market is great – and the data supports the claim.
The femtobrush system from Vital3D promises high-speed and high-precision bioprinting. Credit: vital3d
Commercial views
The global animal wound care market is expected to grow from USD 1.4 billion (EUR 1.24 billion) in 2024 to USD 2.1 billion (EUR 1.87 billion) to 2030 and driven by increasing pet possession and demand for advanced veterinary care. Vital3D predicts an initial breathtable addressable market (ISAM) of € 76.5 million in the EU and the USA. The company plans to sell 100,000 units by 2027-2028.
Dogs are a logical starting point. Their size, activity levels and operations increase your wound risk. About half of the dogs over 10 years are also affected by cancer, which further increases the demand for effective wound care.
With 300 € retail (or € 150 wholesale), the patches are not cheap. However, Vital3D claims that they could reduce the treatment costs for animal owners from € 3,000 to € 1,500. Production on the scale is expected that prices will continue to drop.
After strong results in rats, studies on dogs begin in clinics in Lithuania and Great Britain – Vital3d's pilot markets this summer.
If everything is planned, a non -degradable patch will start in Europe next year. The company will then pass to a biodegradable version.
From there, the company plans to adapt the technology for humans. The initial focus will be wound care for people with diabetes, 25% of whom suffer from impaired healing. Future versions could support combustion victims, injured soldiers and others who need advanced skin recovery.
Freshly printed liquids in a organic-ink droplets. Credit: vital3d
Vital3D also examines other medical limits. In cooperation with the National Cancer Institute in Lithuania, the startup organoid – mini versions of organs – builds for cancer drug tests. Another project includes biofold stents that are promising in early animal experiments. But all of these efforts serve a larger mission.
“Our last goal is to switch to the organ pressure for transplants,” says Šakalys.
Bioprinting organs
Šakalys, a computer engineer of training, has been working with photonic innovations for over 10 years.
At his previous startup, femtics, he used laser to produce tiny components for microelectronics, medical devices and aviation technology. He realized that they could also enable precise bioprinting.
In 2021 he was a co -founder of Vital3D to promote the concept. The company's printing system directs the light to a photosensitive organic in. The material is hardened and formed into a structure, with living cells and biomaterials shaped into complicated 3D patterns.
The shape of the laser beam can be set to replicate complex biological forms – possibly even entire organs.
However, there are still great scientific hurdles to overcome. One is vascularization, the formation of blood vessels in complicated networks. Another is the diverse variety of cell types in many organs. Replication of these sophisticated natural structures will be a challenge.
“First we want to solve the vascular system. Then we will deal with the differentiation of cells,” says Šakalys.
“Our goal is to see whether we can print out of fewer cells, but try to distinguish them while we can print in different types of cells.”
If successful, Vital3D could help reduce the global lack of transplantable organs. According to the World Health Organization, less than 10% of the patients who need transplantation receive. In the United States alone, around 90,000 people are waiting for a kidney – a shortfall that drives a flourishing black market.
Šakalys believes that this could only be the beginning. He stipulates that bioprinting not only creates organs, but also drives a new era of personalized medicine.
“It can bring many advantages to society,” he says. “Not only bioprinting for transplants, but also Tissue Engineering.”
Would you like to discover the next big thing in technology? Then make a trip to the TNW conference at which thousands of founders, investors and innovators share your ideas for companies. The event will take place in Amsterdam from June 19 to 20 and the tickets are now available. Use the Code TNWXMedia2025 at the cash register to get a 30% discount.
